News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Names Bengt Bergstrom, M.D., Ph.D., Vice President, Clinical Development
BOULDER, Colo., Jan 26, 2010 (BUSINESS WIRE) -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that Bengt Bergstrom, M.D., has joined the Company as Vice President of Clinical Development.

With over 30 years of experience as an M.D. / Ph.D. and more than 17 years working in the pharmaceutical industry, Dr. Bergstrom will lead Array's clinical science and drug safety activities for the Company's growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.

"We are very pleased to have someone of Bengt's caliber leading our clinical development group," said Robert E. Conway, Chief Executive Officer. "Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda(R), will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development."

Prior to joining Array, Dr. Bergstrom held various leadership positions within drug development, project management, strategic marketing and business development, and clinical sciences at Hoffmann-La Roche, most recently serving as Clinical Science Leader in oncology drug development. Over the years, he led programs for small molecules, biologics and gene therapy in various therapeutic areas including oncology, inflammation, diabetes, metabolism and neurology. He has experience with Phase 1 through 4 clinical trials and has worked with regulatory agencies around the world. He has worked on six approved New Drug Applications as well as several Investigational New Drug Applications. Dr. Bergstrom studied at the University of Lund in Sweden where he received his M.D. and Ph.D.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to http://www.arraybiopharma.com.

SOURCE: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com